This small cap has landed a BIG deal

Plus check out other biotechs soaring this morning 🦅                                                                                                                                                                                                                                                                                                                                                                                                                 Good day, 360 – Here are our top investing ideas today – these setups look primed! And special alert that Ethan Harms is closing out his [$19 LottoX Trial]( Thursday before his next 0DTE session (last week his picks went 6 for 6 – surely new baby luck 👶!). Let’s see if he can do that again! AVRO - Up over 65% in pre-market after agreeing to sell Cystinosis gene therapy program for $87.5 million to Novartis HEPA - Up over 70% after phase 2 trial success, ahead of conference call review IMMX - Up over 25% in pre after positive Phase 1 cancer treatment trial results 📈 Technical Trade Alert 📈 BIMI International (BIMI)* I want to start off your week with a new stock idea that has the potential to be a very fast mover. If you like small, volatile stocks, then BIMI is definitely one that you should look into today. BIMI has a very high level of insider ownership, a very small float, and a good amount of short interest, as you can see in these stats from [Finviz](… On top of all of that, right now, I think BIMI is setting up perfectly on a technical level. When I overlay my custom trade scanners, you can see that over the last few weeks, BIMI has quietly been building momentum. See the red dots I circled in the chart below? That signals a potential “squeeze pattern” forming. When this happens, a stock is usually going to make a big move (one way or another) in a short period of time. Make sure you understand the risks and rewards of any stock you decide to trade, especially volatile, small-cap stocks like BIMI. A great place to get started is by visiting the company [website]( and learn more about what they are doing. *RagingBull has not been compensated for coverage of BIMI. Please see disclosures below. AVRO - Up over 65% in pre-market after agreeing to sell Cystinosis gene therapy program for $87.5 million to Novartis AVROBIO (AVRO) is a clinical-stage gene therapy company that develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. This morning the company announced it would sell its Cystinosis gene therapy program for $87.5M to Novartis. According to Finviz, AVRO only had a $37M market cap at Friday’s close putting the sale at over 100% value of the company’s shares as of Friday. Noavartis is a $230 billion market cap company so the fact they are buying a program from a small cap such as AVRO is also telling. The $1.25 area was support in the pre-market and will be an important level to watch. Above it, targets to the upside are $1.42, $1.50 and the pre-market high of $1.54. Beyond that, $1.75, $1.93, $2.50, $3 and $4 come into play. Below $1.25, there is potential support at $1.18, $1, $0.88 with a gap to fill at $0.7751. HEPA - Up over 70% after phase 2 trial success, ahead of conference call review Hepion Pharmaceuticals (HEPA), a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. On Friday, the company announced it would be scheduling a conference call review and the stock proceeded to trade over 50% in the after-hours before climbing above 70% in the pre-market. It was then announced that Primary and Secondary endpoints were met in the Phase 2 chronic liver disease therapy trial. $14 was a resistance area in the after-hours and pre-market which now becomes a level of potential support. Above it, targets to the upside are at $16, and then the pre-market high of $16.53. Beyond that, $17.50, $18.50 and $20 come into play. Below $14, there is potential support at $13, $12, $11, $10 and a gap to fill at $8.87. IMMX- Up over 25% in pre after positive Phase 1 cancer treatment trial results Immix Biopharma, Inc (IMMX) a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. Today the company announced positive Phase 1 trial results for its drug NXC-201 showing a 100% overall response rate in the 8 patients in the trial. [Results were as follows](: 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5 ) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS. The $2 area has so far acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are at $2.10, $2.20, $2.30, $2.40 with the pre-market high at $2.49. Beyond that, $3, $3.30, $4 and $5 come into play. Below $2, there is potential support at $1.95, $1.80, $1.75 and a gap to fill at $1.64. Economic Calendar (EST) — tradingeconomics.com To Your Success! *please see disclosures below Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. [RagingBull.com](, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](